JBIO

15.4002.26%
TF

Tom Frohlich

President, CEO & Director

Mr. Tom Frohlich is President, Chief Executive Officer & Director of Jade Biosciences, Inc. since October 2024. Mr. Frohlich serves as Independent Director of Nested Therapeutics since February 2024. He served as the Chief Operating Officer at Chinook Therapeutics, Inc. since June 2021 until August 11, 2023. He serves as an Entrepreneur-in-Residence at Versant Venture Management, LLC since July 2020. He served as Operating Principal at Versant Venture Management, LLC till July 2020. He had been the Chief Business Officer at Chinook Therapeutics, Inc. since January 2019 until June 2021. He is the Senior Vice President of business development at Inception Sciences. Prior to Chinook, from 2014 to 2018, Mr. Frolich had been the Vice President of business development at Arbutus Biopharma, where he successfully sourced and transacted multiple deals. He led Arbutus’ commercial strategy including product evaluation, financial modeling, market research, competitive landscape analysis and business planning. Previously, he worked internationally at J&J and Merck in various roles leading commercial strategy across all stages of product development including the global launches of telaprevir and Stelara. Mr. Frohlich has a BS in biochemistry from the University of Victoria and an MBA from the University of Oxford.

Positions